These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 2851677)
41. Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats. Marc Y; Hmazzou R; De Mota N; Balavoine F; Llorens-Cortes C Biomed Pharmacother; 2021 Aug; 140():111682. PubMed ID: 34020248 [TBL] [Abstract][Full Text] [Related]
42. Enalapril prevents aortic hyperreactivity and remodelling in one-kidney, one-clip hypertensive rats without reducing arterial pressure. Cunha V; Salgado HC; Salgado MC Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):474-9. PubMed ID: 10874501 [TBL] [Abstract][Full Text] [Related]
43. Chronic effects of SQ29,852, a new angiotensin converting enzyme (ACE) inhibitor with a phosphonic acid group, in experimental hypertensive rats. Kishi K; Ikeda M Gen Pharmacol; 1993 Jul; 24(4):863-6. PubMed ID: 8224740 [TBL] [Abstract][Full Text] [Related]
44. Intrarenal angiotensin converting enzyme inhibition in spontaneously hypertensive rats. Aihara H; Ogawa H; Kasuya A; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S Eur J Pharmacol; 1999 May; 373(1):35-40. PubMed ID: 10408249 [TBL] [Abstract][Full Text] [Related]
45. Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE? Schilders JE; Wu H; Boomsma F; van den Meiracker AH; Danser AH Cardiovasc Drugs Ther; 2014 Aug; 28(4):335-45. PubMed ID: 24958603 [TBL] [Abstract][Full Text] [Related]
47. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Friehe H; Ney P Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232 [TBL] [Abstract][Full Text] [Related]
48. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216 [TBL] [Abstract][Full Text] [Related]
49. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Laurent S; Boutouyrie P; Azizi M; Marie C; Gros C; Schwartz JC; Lecomte JM; Bralet J Hypertension; 2000 May; 35(5):1148-53. PubMed ID: 10818079 [TBL] [Abstract][Full Text] [Related]
50. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models. Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773 [TBL] [Abstract][Full Text] [Related]
51. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. French JF; Anderson BA; Downs TR; Dage RC J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349 [TBL] [Abstract][Full Text] [Related]
52. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats. Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; TibiriƧƔ E Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285 [TBL] [Abstract][Full Text] [Related]
53. Hypotensive and physiological effect of angiotensin converting enzyme inhibitory peptides derived from soy protein on spontaneously hypertensive rats. Wu J; Ding X J Agric Food Chem; 2001 Jan; 49(1):501-6. PubMed ID: 11170618 [TBL] [Abstract][Full Text] [Related]
55. Angiotensin-converting enzyme responses following enalapril in the sodium deficient rat. Longman SD; Howlett DR Eur J Pharmacol; 1986 Apr; 123(3):379-86. PubMed ID: 3013653 [TBL] [Abstract][Full Text] [Related]
56. Contribution of the tissue angiotensin converting enzyme to the antihypertensive effect of altiopril calcium (MC-838) in spontaneously hypertensive rats. Kamei K; Shiraki Y; Koga T; Sakai K J Pharm Pharmacol; 1989 Apr; 41(4):279-80. PubMed ID: 2568474 [TBL] [Abstract][Full Text] [Related]
57. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. Natoff IL; Nixon JS; Francis RJ; Klevans LR; Brewster M; Budd J; Patel AT; Wenger J; Worth E J Cardiovasc Pharmacol; 1985; 7(3):569-80. PubMed ID: 2410692 [TBL] [Abstract][Full Text] [Related]
58. [Angiotensin converting enzyme inhibitory activity of MK-0521 in vivo and antihypertensive effect of its single oral administration on blood pressure and effect on the renin-angiotensin system in 2-kidney Goldblatt hypertensive dogs]. Oda M; Ino Y; Suzuki K; Sato T; Iwamoto S; Iwaki M Nihon Yakurigaku Zasshi; 1989 Apr; 93(4):225-34. PubMed ID: 2545579 [TBL] [Abstract][Full Text] [Related]
59. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Tokioka T; Shibasaki M; Fujimori A; Matsuda-Satoh Y; Uchida W; Inagaki O; Yanagisawa I Biol Pharm Bull; 2000 Feb; 23(2):174-81. PubMed ID: 10706380 [TBL] [Abstract][Full Text] [Related]
60. Chronic inhibition of angiotensin converting enzyme decreases Ca2+-dependent tone of aorta in hypertensive rats. Sada T; Koike H; Nishino H; Oizumi K Hypertension; 1989 Jun; 13(6 Pt 1):582-8. PubMed ID: 2737707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]